Together with המרכז הרפואי שיבא, we are pleased to share clinical proof-of-concept results for our novel left atrial appendage closure device. Read more about the minimally invasive device: lnkd.in/dPu5S6H #stroke #medtech

Dr. Stefan Bertog presented our implant-free LAA closure device that is designed to eliminate device-related dangers and reduce #stroke risk in AFib patients at the CRT Meeting this past Saturday, Feb 22. #CRT2020 #cardiovascular

Append is utilizing natural tissue manipulation for complete LAA closure to lower #stroke risk in patients with atrial fibrillation. Read more from Cardiac Rhythm News: bit.ly/2wRyQpe #cardiac #medtech

“We are on a mission to save lives and improve the human condition.” Our CEO had a difficult decision to make: Postpone a pre-clinical trial abroad or proceed as planned and enter a 14-day #quarantine upon return. Read his thoughts: bit.ly/33kNYYp #medtwitter #COVID19

Append Medical has been named one of ‘6 of the Best in Structural Heart’. We are proud that the Appligator has been featured as the next generation transcatheter Left Atrial Appendage (LAA) closure system! bit.ly/2SE5T84 CM Medical #MEDTECH #innovation #cardiac

With Coronavirus having the world need to shelter in place, many non-essential medical procedures are postponed. When dealing with the heart, which is needed for proper bodily function, how do these medical procedures get categorized? To learn more: bit.ly/2Kcw1ma

As an #innovative developer in the field of left atrial appendage closure devices, we are proud to have been included in the recent report showing how our industry’s market is projected to grow at a CAGR of 21.6%. bit.ly/2AF6Bwe #medtech #cardiac

Append Medical’s Appligator is at the forefront of #medtech #innovation for left atrial appendage closure as the solution for a global #stroke risk. Hillel Fuld shares more about our mature #technology in the The Jerusalem Post: bit.ly/2YC10A5 #cardiac

Join Append Medical at the 2020 TCT Connect October 14-18 hosted by Cardiovascular Research Foundation. CEO Zachi Berger will present Append’s suture-based implant-free LAA closure device. To register for the event: bit.ly/3iEbqWu #TCTConnect #TCT2020 #Cardiology

Join Append Medical at the 2020 TCT Connect October 14-18. Dr. Kolja Sievert will be presenting the adaptation of various LAA closure devices. To register for the event: bit.ly/3iEbqWu #TCTConnect #TCT2020 Cardiovascular Research Foundation

We are proud to announce the completion of our first pre-#clinical chronic LAA exclusion procedures using the Appligator device. The success of these procedures validates our approach, which is designed to reduce #stroke risk in AF patients. bit.ly/3eUmheL

“These first procedures provide an important validation for our approach, which is intended to significantly simplify the goal of sealing the LAA and preventing #stroke in AF patients without leaving any implant in the heart”. Read more: bit.ly/35B3S3B #medtech

We're proud to have completed our first pre-clinical chronic procedures utilizing the Appligator, our implant free LAA closure device. bit.ly/32Z8ij2 Cardiovascular News #medtech #innovation #cardiac

Append Medical CEO, Zachi Berger, sat down with IMMR’s Nicolas Borenstein to discuss his insights into the field of #LAA exclusion & share his story of pushing forward pre-clinical trials during the #COVID19 pandemic. To read more: bit.ly/34vjkNI #medtech #innovation

Join Prof Horst Sievert as he moderates the upcoming CSI Congress Virtual Focus LAA webinar on January 29th, 2021 at 17:00 CET. This webinar will focus on new and upcoming devices for #LAA closure, Append Medical included. To register: bit.ly/3pjvS3h #medtech #innovation